Stem Cell Clinic

Fate Therapeutics: 2Q Earnings Snapshot – Albany Times Union

By Stem Cell Treatment

Aug. 5, 2020Updated: Aug. 5, 2020 4:53p.m.

SAN DIEGO (AP) _ Fate Therapeutics Inc. (FATE) on Wednesday reported a loss of $28.1 million in its second quarter.

On a per-share basis, the San Diego-based company said it had a loss of 35 cents.

The results fell short of Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of 20 cents per share.

The clinical-stage biotech company that develops stem cell treatments posted revenue of $5.5 million in the period, which also missed Street forecasts. Nine analysts surveyed by Zacks expected $20.3 million.

Fate Therapeutics shares have climbed 68% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $32.84, an increase of 70% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on FATE at https://www.zacks.com/ap/FATE

Read more from the original source:
Fate Therapeutics: 2Q Earnings Snapshot - Albany Times Union

Fate Therapeutics: 2Q Earnings Snapshot – The Pioneer

By Stem Cell Treatment

Updated 4:53pm EDT, Wednesday, August 5, 2020

SAN DIEGO (AP) _ Fate Therapeutics Inc. (FATE) on Wednesday reported a loss of $28.1 million in its second quarter.

On a per-share basis, the San Diego-based company said it had a loss of 35 cents.

The results fell short of Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of 20 cents per share.

The clinical-stage biotech company that develops stem cell treatments posted revenue of $5.5 million in the period, which also missed Street forecasts. Nine analysts surveyed by Zacks expected $20.3 million.

Fate Therapeutics shares have climbed 68% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $32.84, an increase of 70% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on FATE at https://www.zacks.com/ap/FATE

Read more:
Fate Therapeutics: 2Q Earnings Snapshot - The Pioneer

CF Foundation, Longwood team on new incubator for companies with cutting-edge CF treatments – Endpoints News

By Stem Cell Treatment

Nine months after launching a $500 million hunt for a cure for cystic fibrosis, the Cystic Fibrosis Foundation said it will use a portion of those funds to do something it has never done before: help launch new companies.

The CF Foundation, whose venture philanthropy efforts helped fund Vertexs line of powerful CF drugs, is teaming with Longwood Fund to create a CF incubator. The incubator will identify new companies with platforms or technologies that can be applied in the rare genetic condition. The partners can then finance early development in exchange for a commitment from the companies to focus on applications in cystic fibrosis.

CF Foundation has committed up to $20 million to the effort, although the companies selected could also receive funding through Longwoods traditional early-stage VC efforts.

This is new, so well have to see how it plays out in practice, Longwood partner David Steinberg toldEndpoints News.

The idea for the incubator emerged last October at Harvard Medical School, where Longwood was holding their biannual meeting with non-profits and patient groups. At the time, the CF Foundation was preparing to launch its $500 millionPath to a Cureinitiative. Trikafta, the third of Vertexs three small-molecule CF drugs, was about to hit market, but although the new drug meant 90% of CF patients could now be treated, that still left 10% untreated. Armed with royalties from Vertex, the Pathinitiative would try to back technologies that could treat that last group of patients and ultimately, perhaps, lead to a cure.

The CF Foundation had long backed academic work and particular programs at established companies Vertex kept up their early CF work in part because the foundation was funding it but it had never tried to found new ones. But such an early-stage approach made particular sense for what the foundation was now trying to accomplish, foundation CEO Mike Boyle told Endpoints.

Cystic fibrosis involves a malfunctioning transport protein in the lungs, called CFTR. Vertexs drugs either help that protein fold in the right way or guide it to the right place. Theremaining 10% of patients, though, either have a protein misfolded in such a way it doesnt respond to existing small molecules or they simply dont have the protein at all.

That meant patients would have to be treated with technologies that can target the gene: gene therapy, gene editing, and RNA drugs, among others. Boyle said the foundation is in early talks with 17 biotechs, mostly small, with such platforms. Many larger companies with these platforms are focused in other areas.

One of the challenges right now is that there are easier targets for gene therapy than CF, Boyle said.

Its difficult to get gene therapy into the lungs, where the immune response is unique and cells turn over at a higher rate than in other parts of the body. But the incubator could allow Longwood and the foundation to steer companies that are just starting out to this challenge in exchange for the funding they need to get off the ground. Those startups would also have access to the foundations scientific advisors, their CF lab in Boston and their CF clinical trial network.

In addition to specific therapies, the incubator may also invest in drug delivery technology, such as exosomes, that could make delivering DNA, RNA or other types of drugs to the lungs.

There is precedent for the approach. The Gates Foundations venture arm has long invested in early-stage immunology platforms in exchange for a commitment from the companies to focus part of their work on infectious disease and not just cancer or autoimmune disorders.

Boyle said theyre hoping to launch companies within a couple years, but theyre also continuing to solicit partnerships with academic centers and more established biotechs. The incubators $20 million is just a small portion of Paths $500 million vault.

This is the beginning of the process, Boyle said. We are open for business.

Social image: Mike Boyle, Cystic Fibrosis Foundation via YouTube

Read the original post:
CF Foundation, Longwood team on new incubator for companies with cutting-edge CF treatments - Endpoints News

Allogeneic Stem Cells Market 2020-2024: Business Overview, Industry Size and Share, Opportunities, Impact of Drivers, Key Venders, Types, Applications…

By Stell Cell Research

New product approvals The new product approvals and special drug designations are anticipated to boost the growth of the market. Based on the application, the allogeneic stem cells market has been segmented into regenerative therapy and drug discovery and development. Manufacturers are increasingly emphasizing innovations and improvisation in the development of regenerative therapies. Many of the regenerative therapeutic candidates have obtained approval for clinical trials in the US, Europe, and APAC due to the efficacy of allogeneic stem cell therapeutics. This is encouraging market players to launch new product lines to stimulate the overall product demand for stem or regenerative therapy using allogeneic stem cell therapeutics and provide better options for their customers. Thus, new product approvals will lead to the expansion of the global allogeneic stem cells market at a CAGR of over 12% during the forecast period.

Special drug designations Research in the field of stem cell focuses mainly on developing new treatments for deadly diseases, which have negligible treatment using traditional treatment options. Thus, therapeutic candidates, which are currently under development, have been awarded special drug designations by regulatory bodies considering their proven efficacy. Many drugs received designations such as the breakthrough drug designation and the orphan drug designation from regulatory bodies such as the US FDA and the EMA. Drug designations enhance the research and enable drugs to reach the market and provides strong incentives, which in turn, encourages vendors to expedite R&D on novel therapies such as allogeneic stem cell therapy. This development is expected to have a positive impact on the overall market growth.

Allogeneic Stem Cells Market Report Highlights:

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/15047388

Allogeneic Stem Cells Market Segmentation Covers:

By Type:

Regional Segmentation:

The objective of Studies:

Purchase this Report (Price 2500 USD for single-user license) https://www.industryresearch.co/purchase/15047388

Some Points from Allogeneic Stem Cells Market Report TOC:

PART01:EXECUTIVESUMMARY

PART02:SCOPEOFTHEREPORT

PART03:MARKETLANDSCAPE

PART04:MARKETSIZING

PART05:FIVEFORCESANALYSIS

PART06:MARKETSEGMENTATIONBYTECHNOLOGY

PART07:MARKETSEGMENTATIONBYFURNACETYPE

PART08:CUSTOMERLANDSCAPE

PART09:GEOGRAPHICLANDSCAPE

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

For Detailed TOC Click Here

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Pre-Owned Medical Devices Market Size Outlook 2020 to 2025: Market Trends, Segmentation, Growth Rate and Competitive Landscape with COVID-19 Outbreak

Microsclerotherapy Treatment Market 2020 Global Industry Revenue, Key Strategies, Business Growth Rate by Size, and Top Key Players with COVID-19 Outbreak Forecast to 2025

Weighing Indicators Market Size by Top Key Players 2020 Global Growth Rate by Share, Industry Segment, Future Prospect, Key Finding and Market Dynamics Forecast to 2026

Polyhydric Alcohol Phosphate Ester (PAPE) Market Growth Size, Share 2020 | Industry Analysis with COVID-19 Impact, Company Overview, Key Countries with Future Prospect to 2026

Self-contained Breathing Apparatus (SCBA) Market Share and Size Analysis 2020 by Regional Demand Status, Future Growth Rate, Manufacturers, Trends by Market Dynamics and Development Scope till 2026

Warehouse Management Systems Market 2020 Trends, Manufacturing Size, Growth Analysis by Share, Top Regions, Driving Factors of Manufacturers, Types and Applications Forecast to 2023

Read this article:
Allogeneic Stem Cells Market 2020-2024: Business Overview, Industry Size and Share, Opportunities, Impact of Drivers, Key Venders, Types, Applications...

Here is why AgeX Therapeutics Inc. (AGE) stock volatility recorded over the last month was 14.15% – The InvestChronicle

By Embryonic Stem Cells

Lets start up with the current stock price of AgeX Therapeutics Inc. (AGE), which is $1.52 to be very precise. The Stock rose vividly during the last session to $1.62 after opening rate of $1.10 while the lowest price it went was recorded $1.10 before closing at $1.10.

Recently in News on June 16, 2020, AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic Applications. AgeX Therapeutics, Inc. (AgeX: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Pluristyx, Inc. (Seattle, WA), an advanced therapy tools and services company serving customers in the rapidly growing fields of regenerative medicine and cellular and gene therapies, today announced they have entered into a Manufacturing, Marketing, and Distribution Agreement through which Pluristyx will undertake these activities on behalf of AgeX with respect to AgeXs research- and clinical-grade ESI brand human embryonic stem cells, sometimes referred to as hESCs. You can read further details here

AgeX Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $2.2400 on 01/02/20, with the lowest value was $0.6660 for the same time period, recorded on 04/21/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, AgeX Therapeutics Inc. shares are logging -51.59% during the 52-week period from high price, and 128.23% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $0.67 and $3.14.

The companys shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 4301093 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the AgeX Therapeutics Inc. (AGE) recorded performance in the market was -16.48%, having the revenues showcasing 98.95% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 58.79M, as it employees total of 17 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.9098, with a change in the price was noted +0.7400. In a similar fashion, AgeX Therapeutics Inc. posted a movement of +94.87% for the period of last 100 days, recording 398,960 in trading volumes.

Raw Stochastic average of AgeX Therapeutics Inc. in the period of last 50 days is set at 64.05%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 82.05%. In the last 20 days, the companys Stochastic %K was 44.44% and its Stochastic %D was recorded 34.95%.

Lets take a glance in the erstwhile performances of AgeX Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -16.48%. Additionally, trading for the stock in the period of the last six months notably improved by 16.03%, alongside a downfall of -36.67% for the period of the last 12 months. The shares increased approximately by 23.58% in the 7-day charts and went down by 72.73% in the period of the last 30 days. Common stock shares were driven by 98.95% during last recorded quarter.

Read more here:
Here is why AgeX Therapeutics Inc. (AGE) stock volatility recorded over the last month was 14.15% - The InvestChronicle

FDA touts advanced manufacturing to address Covid-19 shortfalls – Endpoints News

By Stem Cell Medical Center

Advanced manufacturing techniques can be employed to help address some of the manufacturing and supply chain problems the US has seen during the Covid-19 pandemic, Stephen Hahn, FDA commissioner, and Anand Shah, FDA deputy commissioner for medical and scientific affairs, wrote in a blog post on the FDA website.

The potential public health value of advanced manufacturing is even greater in the context of the ongoing COVID-19 pandemic, which has highlighted the strain on supply chains and the need for adaptive manufacturing systems to accelerate the production of medical countermeasures, Hahn and Shahwrote. The FDA has established a strong regulatory foundation to support the uptake of advanced manufacturing, and COVID-19 provides the unique impetus to spur further advancement of medical manufacturing.

They highlighted key regulations the agency has promulgated in recent years to support advanced manufacturing, specifically:

Additional efforts have been undertaken during the current public health emergency, Hahn and Shah pointed out. A multiyear effort between CDER and the US Biomedical Advanced Research and Development Authority (BARDA) is looking at how continuous manufacturing processes can support the production of medical countermeasures. Further, the FDA Office of the Chief Scientist (OCS) and the Center for Devices and Radiological Health (CDRH) are working with the National Institutes of Health and the Departments of Veterans Affairs to share information on 3D printing standards to increase the stock of essential medical supplies including personal protective equipment and certain medical device parts.

FDA also is working within the International Council for Harmonization to make sure that continuous manufacturing guidances are aligned internationally to support innovators, Hahn and Shah wrote.

Because pandemics by nature are unpredictable, our approach to manufacturing must be adaptable. Advanced manufacturing provides an approach for protecting our supply chain and improving our response capacity during crisis situations, they concluded. By establishing the regulatory foundation, the FDA has created a pathway for industry to continue adopting the needed improvements in manufacturing technology for the benefit of public health.

For a look at all Endpoints News coronavirus stories, check out our special news channel.

RAPS: First published in Regulatory Focus by the Regulatory Affairs Professionals Society, the largest global organization of and for those involved with the regulation of healthcare products. Click here for more information.

Here is the original post:
FDA touts advanced manufacturing to address Covid-19 shortfalls - Endpoints News

Fate Therapeutics: 2Q Earnings Snapshot – CT Post

By Stem Cell Treatment

Updated 4:53pm EDT, Wednesday, August 5, 2020

SAN DIEGO (AP) _ Fate Therapeutics Inc. (FATE) on Wednesday reported a loss of $28.1 million in its second quarter.

On a per-share basis, the San Diego-based company said it had a loss of 35 cents.

The results fell short of Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of 20 cents per share.

The clinical-stage biotech company that develops stem cell treatments posted revenue of $5.5 million in the period, which also missed Street forecasts. Nine analysts surveyed by Zacks expected $20.3 million.

Fate Therapeutics shares have climbed 68% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $32.84, an increase of 70% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on FATE at https://www.zacks.com/ap/FATE

Read the original here:
Fate Therapeutics: 2Q Earnings Snapshot - CT Post

Cancer Stem Cell Therapeutics Market Emerging Trends, Business Opportunities, Segmentation, Production Values, Supply-Demand, Brand Shares and…

By Stell Cell Research

Reports and Data has recently added a new research study on the Global Cancer Stem Cell Therapeutics Market to its ever-expanding database. The report is equipped with detailed information about the product types, applications, regions, and key players operating in the market. The report provides a comprehensive analysis of the emerging trends, key challenges, growth potential, drivers, competitive landscape, and industrial chain analysis of the Global Cancer Stem Cell Therapeutics industry.

The latest report is furnished with the impact analysis of the current COVID-19 pandemic on the market. The pandemic has drastically changed the dynamics of the market and has affected every aspect of life globally. The rapidly changing dynamics of the market and current and future growth potential of the market are covered in the report. The report offers crucial information about the initial and future assessment of the impact of the COVID-19 crisis on the overall market.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1414

The report covers an exhaustive analysis of manufacturing processes, development policies, plans, product portfolio, and cost analysis. The data is represented in the form of tables, charts, graphs, diagrams, and figures.

Furthermore, the report includes an in-depth analysis of the competitive landscape. The segment offers a comprehensive overview of the company profiles along with the product profiles, production capacities, products/services, pricing analysis, profit margins, and manufacturing process developments. The report also covers strategic business measures undertaken by the companies to gain substantial market share. The report provides insightful information about recent mergers and acquisitions, product launches, collaborations, joint ventures, partnerships, agreements, and government deals.

The report provides an in-depth analysis of the competitive landscape and covers profiles of key players, along with their product portfolios and business strategies.

Key players of the market mentioned in the report are:

Merck KGA, LONZA Group AG, Novartis, Osiris Therapeutics, Pfizer, Pfizer, Stemline Therapeutics Inc., STEMCELL Technologies, and Thermo Fischer Scientific Inc.

The report analyzes various product types and applications, along with manufacturing and process analysis and cost analysis. The data is further validated via extensive primary and secondary research verified by industry experts and professionals of the profiled companies.

Treatment Type: (Revenue, USD Million; 20162026)

Disease Type: (Revenue, USD Million; 20162026)

Application: (Revenue, USD Million; 20162026)

End Use: (Revenue, USD Million; 20162026)

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1414

Highlights of the Cancer Stem Cell Therapeutics Report:

The report covers historical revenue and sales volume, and the data is validated to provide a forecast market estimation of the market size and sales numbers for key regions along with types and end-user applications. Moreover, the report also includes macroeconomic factors and regulatory policies pertaining to the Cancer Stem Cell Therapeutics industry for evaluation and predictive analysis.

Additionally, the report provides beneficial data about distribution, production, consumption patterns, export/import, and demand and supply ratio. The report covers the latest trends, product portfolio, demographics, regional segmentation, and regulatory framework of the Cancer Stem Cell Therapeutics industry.

Based on the geographical spread, the Cancer Stem Cell Therapeutics industry is segmented into North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa.

Request customization of the report @ https://www.reportsanddata.com/request-customization-form/1414

Highlights of the TOC of the Cancer Stem Cell Therapeutics Market Report:

Global Cancer Stem Cell Therapeutics Market Overview

Global Cancer Stem Cell Therapeutics Market Size and Share by Types

Global Cancer Stem Cell Therapeutics Market Size and Share by Applications

Global Cancer Stem Cell Therapeutics Market Sales and Growth Rate

Global Cancer Stem Cell Therapeutics Market Competitive Landscape

Global Cancer Stem Cell Therapeutics Market Regional Analysis

Global Cancer Stem Cell Therapeutics Market Forecast Estimation (2020-2027)

Global Cancer Stem Cell Therapeutics Market Trends, Drivers, Challenges, Risks, and Opportunities

Global Cancer Stem Cell Therapeutics Market Revenue, Price, and Gross Margin for Each Segment

Global Cancer Stem Cell Therapeutics Market Industrial Chain Analysis

Read more about the TOC in the full report.

To get the Report Description and TOC, visit @ https://www.reportsanddata.com/report-detail/cancer-stem-cell-therapeutics-market

Thank you for reading our report. Customization of this report is available on chapter wise section or region wise. Kindly get in touch with us to know more about the report, and our team will provide the report suited to your needs.

See the original post:
Cancer Stem Cell Therapeutics Market Emerging Trends, Business Opportunities, Segmentation, Production Values, Supply-Demand, Brand Shares and...

Cell Therapy Manufacturing Market to be Worth USD 8 billion by 2030, predicts Roots Analysis – Bulletin Line

By Stem Cell Clinic

Roots Analysis has announced the addition of Cell Therapy Manufacturing Market (2nd Edition), 2018-2030 report to its list of offerings.

Natasha Thakur, the principal analyst, stated, The growing number of cell therapy candidates continues to create an increasing demand for facilities that offer manufacturing services for these complex pharmacological interventions. Presently, over 145 companies / organizations are actively offering manufacturing services for such products. The installed global manufacturing capacity is estimated to be over 1 billion sq ft, with the maximum capacity available in North America

The report presents opinions on several key aspects of the market. Among other elements, it includes:

The report features inputs from a number of eminent industry stakeholders. Thakur remarked, Most of the experts we spoke to confirmed that the manufacturing of cell therapies is largely being outsourced due to exorbitant costs associated with setting-up such facilities. The report features detailed transcripts of discussions held with the following experts:

The research also includes detailed profiles of the following players:

For additional details, please visithttps://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing-market-2nd-edition-2018-2030/209.hl or email [emailprotected]

Contact:

Gaurav Chaudhary

+1-604-595-4954

Link:
Cell Therapy Manufacturing Market to be Worth USD 8 billion by 2030, predicts Roots Analysis - Bulletin Line

Celularity announces the activation of first California Clinical Trial Site following CIRM Grant Award to Advance Treatments for COVID-19 – BioSpace

By Stem Cell Treatment

FLORHAM PARK, N.J., Aug. 5, 2020 /PRNewswire/ --Celularity today announced that it has been awarded a $750,000 COVID-19 Project grant by the California Institute for Regenerative Medicine (CIRM), one of the three clinical awards targeting the coronavirus. This grant will support California Institutions participating in the Phase I/II clinical trial of human placental hematopoietic stem cell derived natural killer (NK) cells (CYNK-001) for the treatment of adults with COVID-19.The University of California Irvine is the first CA site to open for patient enrollment.

CIRM's COVID-19 Project supports promising discovery, preclinical and clinical trial stage projects that could quickly advance treatments or vaccines that utilize stem and/or progenitor cells. Celularity will use the CIRM grant to support the evaluation of the anti-viral activities of its cryopreserved investigational product, CYNK-001, in underserved and disproportionately affected populations with COVID-19, an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Celularity received clearance from the United States Food and Drug Administration to proceed with a Phase I/II study to evaluate the safety, tolerability, and efficacy of CYNK-001 in patients with COVID-19.

"Our investigational product CYNK-001 showed great promise in preclinical studies, and we are optimistic that it will prove effective against corona virus diseases, including COVID-19. As part of our rapidly-scalable placental-derived cellular medicine platform, CYNK-001 could play an important role in the public health response to outbreaks of COVID-19 or other coronaviruses," said Robert J. Hariri, MD, PhD, Founder, Chairman and CEO of Celularity. "We are very grateful to CIRM for supporting our effort to make novel cellular medicines available to medically underserved and disproportionately affected persons in California."

Xiaokui Zhang, PhD, Chief Scientific Officer and Principal Investigator under the CIRM grant says "CYNK-001 has a range of biological activities that not only recognize and destroy virus-infected cells, but also coordinate a robust immune response that may lead to an effective and durable defense against the viral infection."

The trial will evaluate the safety and the clinical efficacy of CYNK-001 in SARS-CoV-2 positive subjects as measured by clearance of the SARS-CoV-2 and improvement in clinical symptoms or improvement in radiological evaluation of disease related chest x-ray. The primary objective of the Phase I portion of the study is to evaluate the safety, tolerability, and efficacy of multiple CYNK-001 intravenous (IV) infusions in COVID-19 patients and will be administered to up to 14 patients in three doses over the course of seven days.

The Phase II portion of the study is a randomized, open-label, multi-site study measuring multiple doses of CYNK-001 against a control group experiencing a similar degree of infection with best supportive care, with two co-primary endpoints. The first co-primary endpoint is to determine the virologic efficacy of CYNK-001 in facilitating the clearance of SARS-CoV-2 from mucosal specimens and/or peripheral blood. The second co-primary endpoint is to assess the impact of treatment with CYNK-001 on clinical symptoms among patients with COVID-19 related lower respiratory tract infection.

Celularity has treated patients with severe COVID-19 and on ventilator support under compassionate use programs in U.S. CYNK-001 was well tolerated and may be associated with clinical benefit in selected cases.

About NK Cells NK cells are innate immune cells with an important role in early host response against various pathogens. Multiple NK cell receptors are involved in the recognition of infected cells. Studies in humans and mice have established that there is robust activation of NK cells during viral infection, regardless of the virus class, and that the depletion of NK cells aggravates viral pathogenesis.

About CYNK-001 CYNK-001 is the only cryopreserved allogeneic, off-the-shelf NK cell therapy developed from placental hematopoietic stem cells. CYNK-001 is being investigated as a potential treatment option in adults with COVID-19, as well as for various hematologic cancers and solid tumors. NK cells are a unique class of immune cells, innately capable of targeting cancer cells and interacting with adaptive immunity. CYNK-001 cells derived from the placenta are currently being investigated as a treatment for acute myeloid leukemia (AML), multiple myeloma (MM), and glioblastoma multiforme (GBM). On 1 April, the U.S. Food and Drug Administration cleared the Company's Investigational New Drug (IND) application for the use of CYNK-001 in adults with COVID-19.

About COVID-19 The virus causing COVID-19 is called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is a novel coronavirus that has not been previously identified. COVID-19 has become a global pandemic, with over 4.2 million confirmed cases in the USA and over 650,000 deaths reported to date worldwide.

About Celularity Celularity, headquartered in Florham Park, N.J., is a next-generation Biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic cellular therapies, at unparalleled scale, quality, and economics. Celularity's innovative approach to cell therapy harnesses the unique therapeutic potential locked within the cells of the post partum placenta. Through nature's immunotherapy engine the placenta Celularity is leading the next evolution of cellular medicine with placental-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases. To learn more visit celularity.com

Media Contact:

Name:Dani Frank

Email:celularity@factorypr.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/celularity-announces-the-activation-of-first-california-clinical-trial-site-following-cirm-grant-award-to-advance-treatments-for-covid-19-301106515.html

SOURCE Celularity

Read more:
Celularity announces the activation of first California Clinical Trial Site following CIRM Grant Award to Advance Treatments for COVID-19 - BioSpace

→←